Deborah Wexler, MD MSc

Massachusetts General Hospital, MA, United States

Novo Nordisk (Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Data monitoring committees)Novo Nordisk (Consultant/Advisory Board, Data Monitoring Committee Service)

Presentation(s):

• Contemporary Trends in the Utilization of Second-line Pharmacological Therapies for Type 2 Diabetes in the United States

  Friday, August 26, 2022
  5:30 PM – 5:45 PM CEST

• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  Friday, August 26, 2022
  6:15 PM – 6:20 PM CEST

• Cardiovascular Outcomes in Patients with Type 2 Diabetes Who Added Either GLP1 Receptor Agonists or DPP4 Inhibitors to SGLT2 Inhibitor Therapy

  Sunday, August 28, 2022
  8:45 AM – 9:00 AM CEST

• Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-head Comparisons

  Sunday, August 28, 2022
  9:15 AM – 9:30 AM CEST

• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  Sunday, August 28, 2022
  9:30 AM – 9:45 AM CEST

• The Comparative Safety of Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis

  Sunday, August 28, 2022
  2:00 PM – 2:15 PM CEST

• Risk of Hypoglycemia with Sodium Glucose cotransporter-2 Inhibitors vs. Alternative Glucose Lowering Medications in Patients with and Without Baseline Use of Insulin or Sulfonylurea

  Sunday, August 28, 2022
  2:30 PM – 2:45 PM CEST